Copyright
©The Author(s) 2021.
World J Cardiol. Mar 26, 2021; 13(3): 46-54
Published online Mar 26, 2021. doi: 10.4330/wjc.v13.i3.46
Published online Mar 26, 2021. doi: 10.4330/wjc.v13.i3.46
Table 1 Baseline characteristics
| Clinic, n (%) | RM, n (%) | |
| n | 45 | 111 |
| Age at implant (year) | 63.6 ± 13.0 | 64.2 ± 11.5 |
| Male | 30 (85.7) | 85 (82.5) |
| NYHA functional class | ||
| I | 12 (34.3) | 40 (38.8) |
| II | 18 (51.4) | 52 (50.5) |
| III | 5(14.3) | 11 (10.7) |
| Cardiac disease category | ||
| Coronary artery disease | 21 (60.0) | 54 (52.4) |
| Non ischaemic dilated cardiomyopathy | 4 (11.4) | 15 (14.6) |
| Primary electrical disease | 3 (8.6) | 5 (4.9) |
| Hypertrophic cardiomyopathy | 1 (2.9) | 6 (5.8) |
| Valvular heart disease | 1 (2.9) | 2 (1.9) |
| Hypertensive | 1 (2.9) | 3 (2.9) |
| Other cardiomyopathy | 1 (2.9) | 5 (4.9) |
| Undetermined | 2 (5.7) | 10 (9.7) |
| None | 1 (2.9) | 1 (1.0) |
| ECG history of | ||
| Sustained ventricular tachycardia | 7 (20.0) | 24 (23.3) |
| Ventricular fibrillation | 6 (17.1) | 19 (18.4) |
| Torsade de pointes | 1 (2.9) | 3 (2.9) |
| Indication for ICD | ||
| Primary | 20 (57.1) | 57 (55.3) |
| Secondary | 15 (42.9) | 46 (44.7) |
| Implanted device | ||
| Single chamber ICD | 13 (37.1) | 27 (26.2) |
| Dual chamber ICD | 19 (54.3) | 74 (71.8) |
| CRT-D | 5 (14.3) | 23 (22.3) |
| Type of implant | ||
| Original | 30 (85.7) | 83 (80.6) |
| Replacement | 5 (14.3) | 20 (19.4) |
| Drug therapy | ||
| Beta-blocker | 25 (71.4) | 69 (70.0) |
| Digoxin | 2 (5.7) | 12 (11.7) |
| Amiodarone | 4 (11.4) | 8 (7.8) |
| Manufacturer | ||
| Biotronik | 11 (31.4) | 44 (42.7) |
| Boston scientific/guidant | 8 (28.8) | 0 (0)1 |
| Medtronic | 5 (14.3) | 41 (39.8) |
| St Jude Medical | 11 (31.4) | 18 (17.5) |
Table 2 Incidence of appropriate and inappropriate shocks and time to medical assessment
| Clinic, n (%) | RM, n (%) | |
| n | 45 | 111 |
| Reason lost to follow up | ||
| Out of area | 3 (6.7) | 4 (3.6) |
| Death | 7(15.6) | 4 (3.6) |
| Number of patients receiving shocks (appropriate) | 3 (8.6) | 14 (13.6) |
| 1 shock | 3 (8.6) | 9 (8.7) |
| 2-9 shocks | 0 | 6 (5.8) |
| ≥ 10 | 0 | 0 |
| Number of patients receiving shocks (inappropriate) | 4 (11.4) | 4 (3.9) |
| 1 shock | 0 | 2 (1.9) |
| 2-9 shocks | 2 (5.7) | 2 (1.9) |
| ≥ 10 | 2 (5.7) | 0 |
| Causes inappropriate shocks (number of shocks) | ||
| AF/flutter | 18 (42.9) | 2 (20.0) |
| SVT | 14 (33.3) | 1 (10.0) |
| T wave over sense | 0 | 1 (10.0) |
| V lead displacement | 0 | 6 (60.0) |
| Noise | 10 (23.8) | 0 |
| TMA | ||
| Appropriate shocks | 11.7 ± 9.2 | 1.8 ± 0.6 |
| Inappropriate shocks | 15.1 ± 6.8 | 1.0 ± 0.0 |
- Citation: Callum K, Graune C, Bowman E, Molden E, Leslie SJ. Remote monitoring of implantable defibrillators is associated with fewer inappropriate shocks and reduced time to medical assessment in a remote and rural area. World J Cardiol 2021; 13(3): 46-54
- URL: https://www.wjgnet.com/1949-8462/full/v13/i3/46.htm
- DOI: https://dx.doi.org/10.4330/wjc.v13.i3.46
